Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Usefulness of optic nerve ultrasound to predict clinical progression in multiple...
Journal Information
Visits
217
Original article
DOI: 10.1016/j.nrleng.2017.12.010
Open Access
Available online 15 November 2019
Usefulness of optic nerve ultrasound to predict clinical progression in multiple sclerosis
Utilidad de la ecografía de nervio óptico como predictor de progresión en esclerosis múltiple
Visits
...
S. Pérez Sáncheza,
Corresponding author
soledad.perez.sanchez@gmail.com

Corresponding author.
, S. Eichau Madueñoa, M. Rus Hidalgoa, A.M. Domínguez Mayorala, A. Vilches-Arenasb, G. Navarro Mascarella, G. Izquierdoa
a Servicio de Neurología, Hospital Universitario Virgen Macarena, Sevilla, Spain
b Servicio de Medicina Preventiva, Hospital Universitario Virgen Macarena, Sevilla, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (6)
Table 1. Baseline characteristics of our sample.
Table 2. Disease characteristics in our sample (n = 63).
Table 3. Correlation between ultrasound findings and presence of relapses and disease progression.
Table 4. Correlation between ultrasound findings and clinical progression during follow-up (Pearson correlation coefficient).
Table 5. Optical coherence tomography results.
Table 6. Correlation between ultrasound findings and optical coherence tomography data (Pearson correlation coefficient).
Show moreShow less
Abstract
Introduction

Progressive neuronal and axonal loss are considered the main causes of disability in patients with multiple sclerosis (MS). The disease frequently involves the visual system; the accessibility of the system for several functional and structural tests has made it a model for the in vivo study of MS pathogenesis. Orbital ultrasound is a non-invasive technique that enables various structures of the orbit, including the optic nerve, to be evaluated in real time.

Methods

We conducted an observational, ambispective study of MS patients. Disease progression data were collected. Orbital ultrasound was performed on all patients, with power set according to the ALARA (“as low as reasonably achievable”) principle. Optical coherence tomography (OCT) data were also collected for those patients who underwent the procedure. Statistical analysis was conducted using SPSS version 22.0.

Results

Disease progression was significantly correlated with ultrasound findings (P = .041 for the right eye and P = .037 for the left eye) and with Expanded Disability Status Scale (EDSS) score at the end of the follow-up period (P = .07 for the right eye and P = .043 for the left eye). No statistically significant differences were found with relation to relapses or other clinical variables.

Discussion

Ultrasound measurement of optic nerve diameter constitutes a useful, predictive factor for the evaluation of patients with MS. Smaller diameters are associated with poor clinical progression and greater disability (measured by EDSS).

Keywords:
Echography
Optic nerve
Progression
Multiple sclerosis
Resumen
Introducción

La pérdida neuronal/axonal progresiva se considera la causa más importante de discapacidad neurológica en la esclerosis múltiple (EM).

El sistema visual está frecuentemente afectado en esta enfermedad y su accesibilidad a test funcionales y estructurales ha permitido que se convierta en un modelo para estudiar in vivo la patogenia. La ecografía orbitaria permite evaluar, de forma no invasiva y en tiempo real, las diversas estructuras de la órbita, incluido el nervio óptico (NO).

Material y métodos

Se ha realizado un estudio observacional ambispectivo en pacientes con EM recogiéndose datos evolutivos de la enfermedad. La ecografía orbitaria se realizó en todos los pacientes según el principio de mínima potencia necesaria. También se recogieron los datos de tomografía de coherencia óptica (OCT) en aquellos que tenían realiza ambas pruebas. El estudio estadístico se realizó con el programa SPSS 22.0.

Resultados

Se encontraron correlaciones estadísticamente significativas entre las medidas ecográficas y la progresión de la enfermedad (p 0.041 para ojo derecho (OD) y p 0.037 para ojo izquierdo (OI), y la EDSS final en el seguimiento (p 0,07 para OD y p 0,043 para OI). No fue así para los datos referentes a brotes y a otras variables clínicas..

Discusión

La medición del diámetro del NO por ecografía podría utilizarse como medida predictiva en la evolución de la enfermedad, ya que la disminución del mismo se asocia con progresión clínica y mayor discapacidad, medidas por EDSS.

Palabras clave:
Ecografía
Nervio óptico
Progresión
Esclerosis múltiple
Full Text
Introduction

Multiple sclerosis (MS) is the most common autoimmune, inflammatory, demyelinating disease of the central nervous system. It is characterised by inflammation, demyelination, axonal degeneration, and neuronal loss.1–3 Recent research has shown that neuronal and axonal damage are largely responsible for disability associated with MS.

The optic nerve is one of the structures most frequently affected in MS4; optic nerve involvement results in a high degree of disability due to its negative impact on quality of life.5 The development of non-invasive techniques such as optical coherence tomography (OCT) has enabled the detection of axonal loss in the anterior visual pathway; the optic nerve has emerged as an accessible model for studying the pathogenesis of MS and monitoring visual symptoms.6

The first study of OCT in patients with MS, published in 1999, showed reduced retinal nerve fibre layer (RNFL) thickness in patients with a history of optic neuritis compared to controls and to the unaffected, contralateral eye.7 Reduced RNFL thickness has also been associated with greater disability as measured with the Expanded Disability Status Scale (EDSS).8,9

Recent studies report that RNFL thickness is correlated with brain atrophy and visual dysfunction; this suggests that the eye may serve as a useful model to study the mechanisms of neurodegeneration in MS, and may even be helpful in studying neuroprotection.10–12 Clinical trials of MS have therefore included OCT to gather exploratory data about changes to the retinal structure and visual function alterations.13 RNFL thickness has been observed to progressively decrease over the course of the disease, even in eyes with no history of optic neuritis.14

Ultrasound is an increasingly widespread technique in neurological diseases; in the context of MS, ocular ultrasound is used to measure optic nerve thickness. Studies using ocular ultrasound report differences in optic nerve diameter between patients with MS and healthy controls, regardless of history of acute optic neuritis. This suggests that ultrasound may be useful in monitoring axonal loss associated with MS due to its ease of use, sensitivity, and reproducibility.15

Patients and methods

We conducted an observational, analytical, ambispective study including a concurrent series of patients. We gathered data on patients attended at the multiple sclerosis unit at Hospital Universitario Virgen Macarena in Seville, Spain; in all cases, optic nerve thickness was determined using ocular ultrasound. The study was approved by our hospital’s ethics committee. All patients gave informed consent.

Inclusion criteria were as follows: age between 18 and 75 years, diagnosis of any form of MS (clinically isolated syndrome, relapsing-remitting, primary progressive, or secondary progressive), and giving informed consent to participate in the study. We excluded all patients younger than 18 or older than 75, those with severe ophthalmological diseases (glaucoma, maculopathy, etc), and those declining to sign the informed consent form.

We used an Esaote® ultrasound system with a 7.5 MHz linear transducer. Ultrasound power was adjusted according to the principle of ALARA (“as low as reasonably achievable”)16; optic nerve thickness was measured longitudinally at 3 mm from the optic disc,15 adjacent to the meningeal layers, due to the difficulty differentiating between axons and meningeal layers in most patients (Fig. 1).

Figure 1.

Ocular ultrasound: longitudinal image of the optic nerve from a patient with multiple sclerosis.

(0.05MB).

We gathered demographic information and retrospective and prospective clinical data. For the prospective study, progression was defined as a sustained increase (> 3 months) of over 0.5 points on the EDSS. We also gathered OCT data from patients who underwent both ocular ultrasound and OCT.

Statistical analysis was conducted using SPSS version 22.0. P-values below .05 were considered statistically significant.

Results

Our sample included 63 patients with MS; all patients underwent ocular ultrasound. Patients were followed up for a mean period of 9.16 months after the ultrasound (range, 3–18 months; SD: 4.37; 95% CI, 8.06–10.26). None of the patients were lost to follow-up.

Table 1 summarises the baseline characteristics of our sample. Mean age at diagnosis was 35.5 years (range, 17–58; SD: 10.06; 95% CI, 32.83–37.90).

Table 1.

Baseline characteristics of our sample.

  n (%)  95% CI 
Sex
Women  43 (68.25)  55.97–80.54 
Men  20 (31.75)  19.46–44.03 
Type of MS
Relapsing  54 (85.71)  76.28–95.15 
CIS  4 (6.35)  1.76–15.47 
RR  50 (79.37)  68.58–90.15 
Progressive  9 (14.29)  4.85–23.72 
PP  7 (11.11)  2.56–19.67 
SP  2 (3.18)  0.39–11.00 
Current treatment
Yes  50 (79.37)  68.58–90.15 
No  13 (20.64)  9.85–31.42 
Current treatment type
1st line  29 (46.03)  32.93–59.13 
Interferon  23 (36.51)  23.83–49.19 
Glatiramer acetate  6 (9.52)  1.48–17.57 
2nd line  21 (33.33)  20.90–45.77 
Natalizumab  8 (12.70)  3.68–21.71 
Fingolimod  11 (17.46)  7.29–27.63 
Other  2 (3.18)  0.39–11.00 
Optic neuritis
Yes  25 (39.68)  26.81–52.56 
No  38 (60.32)  47.44–73.19 

95% CI: 95% confidence interval; CIS: clinically isolated syndrome; MS: multiple sclerosis; PP: primary progressive; RR: relapsing-remitting; SP: secondary progressive.

Table 2 presents retrospective clinical data.

Table 2.

Disease characteristics in our sample (n = 63).

  Range  Mean (SD)  95% CI  Median (p25–p75) 
EDSS score  0–7.5  2.71 (1.96)  2.22–3.21  2 (1.5–4) 
OD visual acuity  0.05–1  0.79 (0.29)  0.72–0.87  1 (0.6–1) 
OS visual acuity  0.05-1  0.79 (0.27)  0.72–0.86  1 (0.6–1) 
MSSS score  0.17–2.35  4.06 (2.76)  3.37–4.76  3.69 (1.77–6) 
No. relapses  0–14  4.35 (3.13)  3.56–5.14  4 (2–6) 
ARR  0-2.83  0.78 (0.61)  0.62–0.93  0.65 (0.37–1) 
Relapses in the past 2 years  0–7  1.30 (1.34)  0.96–1.64  1 (0–2) 
ARR in the past 2 years  0–3.5  0.65 (0.67)  0.48–0.82  0.5 (0–1) 

95% CI: confidence interval; ARR: annualised relapse rate; EDSS: Expanded Disability Status Scale; MSSS: Multiple Sclerosis Severity Scale; OD: right eye; OS: left eye; SD: standard deviation.

Mean optic nerve thickness was 4.54 mm in the right eye (range, 2.29–6.66; SD: 0.95; 95% CI, 4.30–4.78) and 4.63 mm in the left (range, 2.13–5.89; SD: 0.79; 95% CI, 4.43–4.83). The mean difference in optic nerve thickness between the right and the left eye (asymmetry) was 0.69 mm (range, 0–2.20; SD: 0.59; 95% CI, 0.54–0.84).

Ten patients (15.9%) presented relapses during follow-up. We recorded a mean of 0.24 relapses per patient during follow-up (range, 0–3; SD: 0.56; 95% CI, 0.10–0.38), with a mean annualised relapse rate of 0.26 (range, 0–2.40; SD: 0.61; 95% CI, 0.11–0.41). The first relapse appeared after a mean of 7.80 months of follow-up (range, 0.30–17.80; SD: 4.46; 95% CI, 6.68–8.92). Mean EDSS score at the end of the study period was 2.81 (range, 0–7.5; SD: 2.07; 95% CI, 2.29–3.33).

Seventeen patients (27%) showed a sustained increase of over 0.5 points in EDSS scores; disease progression was observed after a mean of 7.90 months (range, 1.87–17.84; SD: 4.17; 95% CI, 6.85–8.95).

The retrospective analysis revealed no significant differences between patients with and without history of optic neuritis in ultrasound results and clinical variables.

Table 3 shows the correlation between ultrasound results and occurrence of relapses and sustained disease progression. Table 4 analyses the correlation between ultrasound results and clinical progression during follow-up.

Table 3.

Correlation between ultrasound findings and presence of relapses and disease progression.

  Right ON diameter  Left ON diameter 
  Range  Mean (SD)  95% CI  P  Range  Mean (SD)  95% CI  P 
Relapses
Yes  10 (3.20–6.67)  4.50 (1.09)  3.73–5.28  ns53 (2.13–5.90)  4.58 (0.94)  3.91–5.25  ns
No  53 (2.29–6.03)  4.55 (0.93)  4.29–4.81  46 (2.29–6.67)  4.69 (0.99)  4.39–4.99 
Disease progression
Yes  17 (3.20–5.60)  4.14 (0.69)  3.79–4.49  .04153 (2.13–5.90)  4.58 (0.94)  3.91–5.25  .037
No  46 (2.29–6.67)  4.69 (0.99)  4.39–4.99  46 (2.13–5.90)  4.72 (0.82)  4.48–4.97 

95% CI: 95% confidence interval; ns: not significant; ON: optic nerve; SD: standard deviation.

Statistically significant results are shown in bold (P < .05).

Table 4.

Correlation between ultrasound findings and clinical progression during follow-up (Pearson correlation coefficient).

  Right ON diameter  P  Left ON diameter  P  Mean ON asymmetry  P 
EDSS score  –0.338  .007  –0.256  .043  –0.125  ns 
No. relapses  –0.083  ns  0.092  ns  –0.006  ns 
ARR  –0.094  ns  0.085  ns  –0.020  ns 
Time to relapse  0.025  ns  0.046  ns  0.066  ns 
Time to progression  0.167  ns  0.140  ns  0.201  ns 

ARR: annualised relapse rate; EDSS: Expanded Disability Status Scale; ns: not significant; ON: optic nerve.

Statistically significant results are shown in bold (P < .05).

Fifty-two patients were assessed with OCT, although only 50 underwent OCT of both eyes. In the remaining 2 patients, OCT could not be performed bilaterally for technical reasons (severe nystagmus, which prevented eye fixation). OCT results are shown in Table 5. Table 6 shows data on the relationship between ultrasound findings and OCT results.

Table 5.

Optical coherence tomography results.

  Range  Mean (SD)  95% CI  Median (p25–p75) 
RNFL thickness
OD  50 (44–106)  85.24 (14.08)  81.24–89.24  89 (77.50–96) 
OS  51 (38–109)  83.88 (14.93)  79.68–88.08  86 (76–94) 
GCL thickness
OD  50 (49–92)  75.74 (11.05)  72.60–78.88  77 (69.75–83.25) 
OS  52 (51–94)  75.58 (10.69)  72.60–78.55  76.5 (68.25–83.75) 
Minimum GCL thickness
OD  50 (26–89)  70.14 (13.78)  66.22–74.06  73 (62.75–81) 
OS  52 (21–92)  71.48 (13.88)  67.62–75.35  74.50 (64–80.75) 

95% CI: 95% confidence interval; GCL: ganglion cell layer; OD: right eye; OS: left eye; RNFL: retinal nerve fibre layer; SD: standard deviation.

Table 6.

Correlation between ultrasound findings and optical coherence tomography data (Pearson correlation coefficient).

  Right ON diameter  P  Left ON diameter  P  Mean ON asymmetry  P 
RNFL thickness, OD  0.281  .048  0.202  ns  0.005  ns 
RNFL thickness, OS  0.192  ns  0.132  ns  0.029  ns 
Mean GCL thickness, OD  0.313  .027  0.276  ns  –0.021  ns 
Mean GCL thickness, OS  0.058  ns  0.199  ns  0.091  ns 
Minimum GCL thickness, OD  0.231  ns  0.307  .030  –0.056  ns 
Minimum GCL thickness, OS  0.025  ns  0.189  ns  0.107  ns 

GCL: ganglion cell layer; ns: not significant; OD: right eye; ON: optic nerve; OS: left eye; RNFL: retinal nerve fibre layer.

Statistically significant results are shown in bold (P < .05).

Discussion

Central nervous system lesions associated with MS are characterised by disruption of the blood-brain barrier, inflammation, demyelination, oligodendrocyte loss, reactive gliosis, and neuronal/axonal degeneration.1,17,18 Progressive neuronal/axonal loss, the most important factor in the development of neurological disability associated with MS, is detectable at very early stages of the disease.19

Ocular ultrasound has previously been used to evaluate the optic nerve in patients with intracranial hypertension20 and acute optic neuritis.21 Compared to 3 T MRI, ocular ultrasound shows good measurement accuracy, reproducibility, and inter- and intra-observer agreement.22 Our patients’ ultrasound results are similar to those reported in other studies23; the same is true for clinical and disease progression data.

Our patients scored slightly higher on the EDSS at the end of the study period than at baseline; this is to be expected due to disease progression.24,25 We found a statistically significant negative correlation between optic nerve diameter and EDSS scores: smaller diameter was correlated with higher EDSS scores at the end of the study.

We also observed significant differences in optic nerve diameter between patients who showed disease progression and those who did not: diameter was smaller in both eyes in patients showing disease progression. However, no correlation was observed between optic nerve diameter and presence of relapses, number of relapses, annualised relapse rate, or time to first relapse. This is explained by the inflammatory component of relapses. Disease progression and disability (EDSS), in turn, are linked to neurodegeneration and axonal loss.26 These changes can be evaluated with ultrasound. Similarly, RNFL thickness and/or brain volume have been regarded as surrogate markers of axonal damage.27

No study has analysed the association between optic nerve thickness as measured with ultrasound and OCT findings in patients with MS, as ultrasound has only recently been introduced in this field and is still under study. However, the literature does include studies of ocular haemodynamic parameters, mainly in the context of optic neuritis.28–32 We found a significant positive correlation between optic nerve diameter as measured with ultrasound and OCT results for RNFL thickness and mean thickness of the ganglion cell layer in the right eye. This positive correlation suggests that ultrasound is a simple yet less precise technique, since it cannot differentiate between layers. Ultrasound results give an approximate idea of the integrity of the optic nerve in these patients. Differences between eyes in our sample may be due to the higher frequency of history of optic neuritis in the right eye (20.6%, vs 15.9% in the left eye). Further research is needed to confirm this hypothesis, however.

Ultrasound measurements of optic nerve diameter may help predict disease progression, since a decrease in optic nerve diameter is associated with clinical progression and greater disability during follow-up. In the absence of a gold standard for evaluating neurodegeneration and axonal damage, optic nerve ultrasound constitutes a useful tool for the assessment of patients with MS, although further research is necessary to confirm our results.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
S.L. Hauser, J.R. Chan, J.R. Oksenberg.
Multiple sclerosis: prospects and promise.
Ann Neurol, 74 (2013), pp. 317-327
[2]
H.F. McFarland, R. Martin.
Multiple sclerosis: a complicated picture of autoimmunity.
Nat Immunol, 8 (2007), pp. 913-919
[3]
A. Nylander, D.A. Hafler.
Multiple sclerosis.
J Clin Invest, 122 (2012), pp. 1180-1188
[4]
R.E. Sakai, D.J. Feller, K.M. Galetta, S.L. Galetta, L.J. Balcer.
Vision in multiple slcerosis (MS): the story, structure-function, correlations, and models for neuroprotection.
J Neuroophthalmol, 31 (2011), pp. 362-373
[5]
A. Gónzalez Gomez, A. García Ben, A. Soler García, I. García Basterra, F. Padilla Parrado, J.M. García Campos.
Estudio longitudinal de función visual en pacientes con esclerosis múltiple remitente-recurrente con y sin antecedentes de neuritis óptica..
Neurología, pii: S0213-4853 (2017), pp. 30024-30025
[6]
S.S. Qureshi, S.C. Beh, T.C. Frohman, E.M. Frohman.
An update on neuro-ophthalmology of multiple sclerosis: the visual system as a model to study multiple sclerosis.
Curr Opin Neurol, 27 (2014), pp. 300-308
[7]
V. Parisi, G. Manni, M. Spadaro, G. Colacino, R. Restuccia, S. Marchi, et al.
Correlation between morphological and functional retinal impairment in multiple sclerosis patients.
Invest Ophthalmol Vis Sci, 40 (1999), pp. 2520-2527
[8]
A. Petzold, J.F. De Boer, S. Schippling, P. Vermersch, R. Kardon, A. Green, et al.
Optical coherence tomography inmuliple sclerosis: a systematic review and meta-analysis.
Lancet Neurol, 9 (2010), pp. 921-932
[9]
A. Soler García, F. Padilla Parrado, L.C. Figueroa Ortiz, A. Gonzá-lez Gómez, A. García-Ben, E. García-Ben, et al.
Analisis of macular and nerve fiber layer thickness in multiple sclerosis patients according to severity level and optic neuritis episodies.
Neurología, 31 (2016), pp. 379-388
[10]
E.M. Frohman, J.G. Fujimoto, T.C. Frohman, P.A. Calabresi, G. Cutter, L.J. Balcer.
Optial coherence tomography: a window into the mechanisms of multiple sclerosis.
Nat Clin Pract Neurol, 4 (2008), pp. 664-675
[11]
J.N. Ratchford, S. Saidha, E.S. Sotirchos, J.A. Oh, M.A. Sergio, E.C. Eckstein, et al.
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.
[12]
S. Saidha, O. Al-Louzi, J.N. Ratchford, P. Bhargaba, S.D. Newsome, J.L. Prince, et al.
Optical coherence tomography reflects brain atrophy in MS. A four year study.
Ann Neurol, 78 (2015), pp. 801-813
[13]
K.M. Galetta, L.J. Balcer.
Optical coherence tomography to monitor axonal and neuronal integrity in multiple sclerosis.
En: Multiple Sclerosis Therapeutics, fourth edition, Cambridge University Press, (2011), pp. 213
[14]
L.S. Talman, E.R. Bisker, D.J. Sackel, D.A. Long Jr, K.M. Galetta, J.N. Ratchford, et al.
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis.
Ann Neurol., 67 (2010), pp. 749-760
[15]
J. Fernández-Domínguez, R. García-Rodrígez, V. Mateos.
Utilidad del dúplex orbitario para la valoración de atrofia del nervio óptico en enfermedades desmielinizantes: estudio piloto.
Rev Neurol, 54 (2012), pp. 587-592
[16]
J.A. Rojo Aladro.
Estudio ultrasonográfico de la orbita.
En: Neurosonologia: aplicaciones diagnósticas para la práctica clínica, Madrid, (2011), pp. 347-362
[17]
B.F.G. Popescu, C.F. Lucchinetti.
Pathology of demyelinating diseases.
Ann Rev Pathol, 7 (2012), pp. 185-217
[18]
B.D. Trapp, P.K. Stys.
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis.
Lancet Neurol, 8 (2009), pp. 280-291
[19]
F.J. Quintana, A. Yeste, I.D. Mascanfroni.
Inmunopatología de la esclerosis múltiple.
En: Neurodegeneración en la esclerosis múltiple, Barcelona, (2015), pp. 7-25
[20]
T. Geeraerts.
Noninvasive surrogates of intracranial pressure: another piece added vith magnetic resonance imaging of the cerebrospinal fluid thickness surroundin the optic nerve.
Critical Care, 17 (2013), pp. 187
[21]
A. Dehgani, M. Giti, M.R. Akhlagi, M. Karmai, F. Salehi.
Ultrasonography in distinguishing optic neuritis from nonarteritic anterior ischemic optic neuropathy.
Adv Biomed Res, 1 (2012), pp. 3
[22]
J. Bäuerle, F. Schuchardt, L. Schroeder, K. Egger, M. Weigel, A. Harloff.
Reproducibility and accuracy of optic nerve sheath diameter assessment usin ultrasound compared to magnetic resonance imaging.
BMC Neurol, 13 (2013), pp. 187
[23]
N. Carraro, G. Servillo, V.M. Sarra, A. Bignamini, G. Pizzolato, M. Zorzon.
Optic nerve and its arterial-venous vascularization: an ultrasonologic study in multiple sclerosis patients and healthy controls.
J Neuroimaging, 24 (2014), pp. 273-277
[24]
S.J. Pittock, W.T. Mayr, R.L. McClelland, N.W. Jorgensen, S.D. Weigand, J.H. Noseworthy, et al.
Disability profile of MS did not change over 10 years in a population-based prevalence cohort.
Neurology., 62 (2004), pp. 601-606
[25]
M. Trojano, C. Avolio, C. Manzari, A. Calò, F. De Robertis, G. Serio, et al.
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.
J Neurol Neurosurg Psychiatry, 58 (1995), pp. 300-306
[26]
M. Comabella López.
Marcadores de neurodegeneración.
En: Neurodegeneración en la esclerosis múltiple, Barcelona, (2015), pp. 25-46
[27]
E.H. Martínez-Lapiscina, E. Fraga-Pumar, I. Gabilondo, E. Martínez-Heras, R. Torres-Torres, S. Ortiz-Pérez, et al.
The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.
BMC Res Notes, 7 (2014), pp. 910
[28]
C. Akarsu, F.U. Tan, T. Kendi.
Color Doppler imaging in optic neuritis with multiple sclerosis.
Graefes Arch Clin Exp Ophthalmol, 242 (2004), pp. 990-994
[29]
M. Modrzejewska, D. Karczewicz, G. Wilk.
Assessment of blood flow velocity in eyeball arteries in multiple sclerosis patients with past retrobulbar optic neuritis in color Doppler ultrasonography.
Klin Oczna, 109 (2007), pp. 183-186
[30]
P. Hradílek, P. Stourac, M. Bar, O. Zapletalová, D. SKoloudik.
Colour Doppler imaging evaluation of blood flow parameters in the ophthalmic artery in acute and chronic phases of optic neuritis in multiple sclerosis.
Acta Ophthalmol, 87 (2009), pp. 65-70
[31]
M. Karami, M. Janghorbani, A. Dehghani, M. Riahinejad.
Orbital doppler evaluation of blood flow velocities in optic neuritis.
Korean J Ophthalmol, 26 (2012), pp. 116-122
[32]
H.T. Akcam, I.Y. Capraz, Z. Aktas, H.Z. Batur Caglayan, S. Ozhan Oktar, M. Hasanreisoglu, et al.
Multiple Sclerosis and optic nerve: an analysis of retinal nerve fiber layer thickness and colo doppler imaging parameters.
Eye (London), 28 (2014), pp. 1206-1211

Please cite this article as: Pérez Sánchez S, et al. Utilidad de la ecografía de nervio óptico como predictor de progresión en esclerosis múltiple. Neurología. 2017. https://doi.org/10.1016/j.nrl.2017.12.009

This study was presented at the 68th Annual Meeting of the Spanish Society of Neurology (poster and oral communication), the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (poster), and the 22nd Meeting of the European Society of Neurosonology and Cerebral Hemodynamics (poster).

Copyright © 2018. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.